EUVIMEDEUVIMED entdecken
Systematische Übersicht

Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023

Christina A Nelson, Jessica Winberg, Taylor D Bostic, K Meryl Davis, Shannon Fleck-Derderian

Clinical Infectious Diseases · 31.01.2024 · 78 (Supplement_1) · S15-S28

DOI: 10.1093/cid/ciad736 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Infectious Diseases, online erschienen am 31.01.2024. Verfasst von Christina A Nelson und 4 weiteren Autor:innen. Beteiligte Einrichtung: Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Tularemia, Francisella tularensis. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: CDC HHS, ASPR HHS, Centers for Disease Control and Prevention.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Francisella tularensis, the causative agent of tularemia, is endemic throughout the Northern Hemisphere and requires as few as 10 organisms to cause disease, making this potential bioterrorism agent one of the most infectious bacterial pathogens known. Aminoglycosides, tetracyclines, and, more recently, fluoroquinolones are used for treatment of tularemia; however, data on the relative effectiveness of these and other antimicrobial classes are limited.

Methods

Nine databases, including Medline, Global Health, and Embase, were systematically searched for articles containing terms related to tularemia. Articles with case-level data on tularemia diagnosis, antimicrobial treatment, and patient outcome were included. Patient demographics, clinical findings, antimicrobial administration, and outcome (eg, intubation, fatality) were abstracted using a standardized form.

Results

Of the 8878 publications identified and screened, 410 articles describing 870 cases from 1993 to 2023 met inclusion criteria. Cases were reported from 35 countries; more than half were from the United States, Turkey, or Spain. The most common clinical forms were ulceroglandular, oropharyngeal, glandular, and pneumonic disease. Among patients treated with aminoglycosides (n = 452 [52%]), fluoroquinolones (n = 339 [39%]), or tetracyclines (n = 419 [48%]), the fatality rate was 0.7%, 0.9%, and 1.2%, respectively. Patients with pneumonic disease who received ciprofloxacin had no fatalities and the lowest rates of thoracentesis/pleural effusion drainage and intubation compared to those who received aminoglycosides and tetracyclines.

Conclusions

Aminoglycosides, fluoroquinolones, and tetracyclines are effective antimicrobials for treatment of tularemia, regardless of clinical manifestation. For pneumonic disease specifically, ciprofloxacin may have slight advantages compared to other antimicrobials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TularemiaFrancisella tularensisHumansAnti-Bacterial AgentsCiprofloxacinAminoglycosidesTetracyclines

Stichwörter der Autor:innen

Francisella tularensisaminoglycosidesfluoroquinolonestetracyclinestularemia

Substanzen

Anti-Bacterial AgentsCiprofloxacinAminoglycosidesTetracyclines

Autor:innen und Institutionen

  • Bacterial Diseases Branch, Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
  • Alaka`ina Foundation, Contracting Agency for Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, USA.
  • Oak Ridge Institute of Science and Education, Centers for Disease Control and Prevention Fellowship Program, Oak Ridge, Tennessee, USA.
  • Gilstrap Obstetrics and Gynecology Fellow, CDC Foundation, Atlanta, Georgia, USA.

Förderung

  • CDC HHS
  • ASPR HHS
  • Centers for Disease Control and Prevention
  • Office of the Assistant Secretary for Preparedness and Response
  • US Department of Health and Human Services

Zitieren

APA

Nelson, C. A., Winberg, J., Bostic, T. D., Davis, K. M., & Fleck-Derderian, S. (2024). Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023. Clinical Infectious Diseases, 78(Supplement_1), S15-S28. https://doi.org/10.1093/cid/ciad736

Vancouver

Nelson CA, Winberg J, Bostic TD, Davis KM, Fleck-Derderian S. Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023. Clinical Infectious Diseases. 2024;78(Supplement_1):S15-S28. doi:10.1093/cid/ciad736

BibTeX
@article{Nelson2024,
  author = {Nelson, Christina A and Winberg, Jessica and Bostic, Taylor D and Davis, K Meryl and Fleck-Derderian, Shannon},
  title = {Systematic Review: Clinical Features, Antimicrobial Treatment, and Outcomes of Human Tularemia, 1993–2023},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  volume = {78},
  number = {Supplement_1},
  pages = {S15--S28},
  doi = {10.1093/cid/ciad736}
}
Kostenlos starten →